Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Louisiana for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Louisiana only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Louisiana (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Frankie Pedigo (NPI 1700240504)

Field	Value
Entity Type	Individual
Organization	Frankie Pedigo
Address	820 Jordan St Ste 201
City	Shreveport
State	LA
ZIP	71101
Taxonomy	Rheumatology Physician
NPI Enumerated	April 7, 2016

Payer Source	Total Paid
Medicare	$1.2M
Medicaid	$0

Key Findings

This provider is effectively single‑payer: Total Medicare revenue is $1.2M and there is no Medicaid billing on file, so the observed billing footprint is concentrated in Medicare rather than split across both programs. Analysts should treat this profile as Medicare‑centric when modeling payer mix or network participation.

Revenue is highly concentrated in a small set of infused/ injectable drug codes: the precomputed top 3 Medicare codes (J1602, J0129, J3111) account for 65.9% of the provider's total Medicare revenue. Those three codes are J1602 ($388.5K revenue, 33.9% of Medicare revenue), J0129 ($211.7K revenue, 18.5%), and J3111 ($154.6K revenue, 13.5%), indicating that a majority of dollars flow from biologic or bone‑targeted injectable therapies.

The code mix and line items indicate an in‑office infusion/administration model centered on biologics and bone agents: high revenue and large claim counts for J1602 (38.9K claims), J0129 (6.2K claims), J3111 (19.3K claims) and meaningful revenue from J0897 ($135.1K) and J3262 ($88.6K) point to routine parenteral administration of specialty biologic products rather than solely clinic E/M revenue. Chemotherapy/infusion administration codes are present at smaller levels (96413 $31.3K, 96401 $17.5K), which supports the presence of an infusion capability but not a large oncology practice.

Competitive standing on the top revenue drugs is mixed and generally modest: J1602 ranks #91 of 1041 nationally (91th percentile) and is characterized as typical, unremarkable volume for the code, J0129 ranks #796 of 1221 (35th percentile) labeled typical, unremarkable volume, and J3111 ranks #352 of 970 (63th percentile) labeled typical, unremarkable volume. Taken together, these rank/percentile signals suggest the provider is not a dominant national leader on these specific drugs but is an established, regular user of them.

Several non‑drug procedure codes are statistical outliers compared with peers and may reflect local practice patterns or service line specialization: 72072 (thoracic spine X‑rays) is an extreme outlier at the 99th percentile with $3.4K revenue, 73100 (wrist X‑rays) and 73130 (hand X‑rays) appear notably above typical national volume at the 98th and 97th percentiles respectively ($5.1K and $5.8K revenue), and 99205 (high‑complexity new patient E/M) is notably above typical national volume at the 97th percentile with $18.7K revenue. These elevated imaging and high‑complexity new‑visit signals suggest the practice may perform a higher-than-typical share of diagnostic imaging and complex new evaluations for its patient mix.

The provider shows a measurable E/M footprint but it is secondary to drug/infusion revenue: 99215 generated $22.2K and 99214 generated $13.9K in Medicare revenue, while 99205 (new patient, high complexity) produced $18.7K and is noted as notably above typical national volume. This pattern—modest ongoing established‑patient E/M revenue combined with relatively high 99205 activity—may indicate periodic referral of complex new patients into an infusion‑centric practice.

Tenure and operational implications: the NPI was enumerated 2016-04-07 (~10 years ago), indicating roughly a decade of billing history under this identifier. Combined with the heavy reliance on in‑office biologic administration (top drug codes), the practice profile is consistent with an established rheumatology infusion/provider model whose revenue will be sensitive to changes in Medicare drug reimbursement, formulary/access dynamics, and prescribing of the small set of high‑revenue injectable agents.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

25 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J1602	Injection, golimumab, 1 mg, for intravenous use	38,850	$10	$388.5K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	6,230	$30	$211.7K
J3111	Injection, romosozumab-aqqg, 1 mg	19,320	$10	$154.6K
J0897	Injection, denosumab, 1 mg	7,500	$20	$135.1K
J3262	Injection, tocilizumab, 1 mg	17,720	$10	$88.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	340	$90	$31.3K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	6,200	$1	$24.8K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	170	$130	$22.2K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	120	$160	$18.7K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	340	$50	$17.5K

Showing 1–10 of 25

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 25 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Louisiana Distribution

Frankie Pedigo — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Louisiana

Full comparison — all codes billed, vs. state median

25 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J1602	6	10	26,920	$10	$526.5K
J0129	11	10	9,490	$30	$506.1K
J3262	5	10	55,770	$1	$329.7K
J0717	9	10	55,200	$1	$263K
J3111	5	10	16,800	$10	$161.1K
J0897	18	70	3,120	$20	$105.6K
96413	16	70	140	$90	$22.8K
99214	2,641	6,670	110	$80	$16.5K
96401	8	50	130	$50	$12.9K
99215	167	1,650	40	$110	$8.4K

Showing 1–10 of 25

Related Providers

Other providers that share a Tax Identification Number (TIN) with Frankie Pedigo, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Aaron Broadwell	LA	Rheumatology Physician	$6.4M	$0
Larry Broadwell	LA	Rheumatology Physician	$5M	$0
Mary Walton	LA	Rheumatology Physician	$952.9K	$0
Mamatha Katikaneni	LA	Rheumatology Physician	$473.3K	$0
Emily Bergeron	LA	Physician Assistant	$11.9K	$0

Nearby Providers

Other providers in the same ZIP code as Frankie Pedigo, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The Arc Caddo Bossier	LA	Health Maintenance Organization	$0	$37.3M
Volunteers Of America Of North Louisiana	LA	Developmentally Disabled Services Day Training Agency	$0	$24.2M
City Of Shreveport	LA	Ambulance	$1.5M	$20.2M
Assisted Family Services, LLC.	LA	In Home Supportive Care Agency	$0	$19.8M
Ochsner Lsu Health Shreveport - St. Mary Medical Center, LLC	LA	Women's Hospital	$0	$15M
Volunteers Of America Of North Louisiana	LA	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$12.5M
Brentwood Acquisition-shreveport Inc.	LA	Psychiatric Hospital	$0	$11.2M
Easter Seals Louisiana Inc.	LA	Case Management Agency	$0	$9.8M
Center For Behavioral Health Louisiana LLC	LA	Methadone Clinic	$299.3K	$7.1M
Progressive Childrens Clinic LLC	LA	Pediatrics Physician	$0	$6.1M

Frankie Pedigo — Billing Profile & Reimbursement Data

Sign up for Frankie Pedigo — Billing Profile & Reimbursement Data policy alerts

Frankie Pedigo — Billing Profile & Reimbursement Data

Sign up for Frankie Pedigo — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References